Konjet Pharmaceuticals (00867) announced its interim performance as of June 30, 2024. The company's attributable profit for the period was 91 billion yuan (RMB, same below), a year-on-year decrease of 52.6%. Basic earnings per share were 0.3734 yuan. The proposed interim dividend is 0.1507 yuan per share.
During the period, the company's operating revenue was 3.611 billion yuan, a year-on-year decrease of 21.67%.
The group's Yousifu and Boyiding will continue to implement the eighth batch of national quantity procurement (national procurement), which will have a negative impact on business performance; the three national procurement products (Dailixin, Yousifu, and Boyiding) have a decrease of RMB 1.197 billion in sales revenue from pharmaceuticals in the same period last year and a year-on-year decrease of 49.2%. In the first half of 2024, the group's non-national procurement exclusive products and innovative products had a total sales revenue of 2.405 billion yuan from pharmaceuticals, accounting for 56.1% of total pharmaceutical sales revenue.
